Skip to main content
Premium Trial:

Request an Annual Quote

PathoGenome 2.0 Offers Better Bioinformatics Platform, More Data

Premium

WALTHAM, Mass.--Genome Therapeutics here has released version 2.0 of PathoGenome, the company's proprietary microbial sequence database. The new version uses a more powerful and efficient bioinformatics platform and features highly finished genomic sequence information for more than a dozen pathogens, according to the company.

The upgraded PathoGenome is currently being installed at the research facilities of the database's subscribers, who include Bayer, Bristol-Myers Squibb, and Schering-Plough. The original version was introduced in May. "The feedback we've received from our customers has been excellent, with reports of new potential antiinfective targets already identified. This rapid success underscores the power of comparative genomics to define targets that are common to multiple organisms," commented Robert Hennessey, Genome Therapeutics' chairman, president, and CEO.

Filed under

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.